- Conditions
- Colorectal Adenoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Carcinoma, Colorectal Tubulovillous Adenoma
- Interventions
- Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 4:15 AM EDT